Page 10 - PRESENTATION

“What is germline mutational landscape in unselected patients with prostate cancer?”

“Do guidelines adequately identify patients at risk for aggressive disease?”

• Inherited mutations have considerable

implications at presentation for staging,

screening and treatment

• Current NCCN guidelines recommend genetic

testing for all patients with metastatic, regional, 25

very high-risk disease or high-risk disease Among the patients with

regardless of family history 20 positive findings,

proportion by gene

• This cross-sectional study of 3607 men found 15

that 620 (17%) had a pathogenic germline Percentage of Total Positive Findings

variant, of which 229 (37%) did not qualify for 10

genetic testing per NCCN recommendations

5

• Conclusion: simplification and expansion of

testing guidelines will improve medical 0

management of these patients

Requisitioned Gene

11 Nicolosi P et al. JAMA Oncol. doi:10.1001/jamaoncol.2018.6760 Published online February 7, 2019.